NRX Pharmaceuticals, Inc. revenue by segment NRXP

NRX Pharmaceuticals, Inc. splits its revenue into 2 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Therapy at $871,000, 79% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line
TTM
Jun 30, 2026
Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Q2 FY2024
Jun 30, 2025
Q1 FY2024
Mar 31, 2025
Q4 FY2024
Dec 31, 2024
Q3 FY2024
Sep 30, 2024
Q4 FY2023
Dec 31, 2023
Q3 FY2023
Sep 30, 2023
Revenue
—
1
1
0
0
0
0
—
—
Therapy
—
1
share 79.1%
1
share 71.2%
—
—
—
—
—
—
Procedures
—
0
share 20.9%
0
share 28.8%
—
—
—
—
—
—
How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
NRXP (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Wilmington, DE
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1719406
Former names
Big Rock Partners Acquisition Corp. (until May 24, 2021)

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.